Discriminative Stimulus Effects of Substituted Tryptamines in Rats.
暂无分享,去创建一个
[1] G. Knudsen,et al. Plasma psilocin critically determines behavioral and neurobiological effects of psilocybin , 2020, Neuropsychopharmacology.
[2] Matthew W. Johnson,et al. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan , 2020, Psychopharmacology.
[3] J. Wallach,et al. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species , 2020, Neuropharmacology.
[4] R. Stevenson,et al. A systematic study of microdosing psychedelics , 2018, PloS one.
[5] C. Svarer,et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels , 2019, Neuropsychopharmacology.
[6] Haden Geiger,et al. DARK Classics in Chemical Neuroscience: Psilocybin. , 2018, ACS chemical neuroscience.
[7] Mark I. Johnson,et al. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? , 2018, Pain management.
[8] M. Farré,et al. Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis , 2017, Journal of psychoactive drugs.
[9] D. van der Kooy,et al. A single administration of the hallucinogen, 4‐acetoxy‐dimethyltryptamine, prevents the shift to a drug‐dependent state and the expression of withdrawal aversions in rodents , 2017, The European journal of neuroscience.
[10] Matthew W. Johnson,et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.
[11] M. Barratt,et al. Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States. , 2016, The American journal on addictions.
[12] M. Liechti,et al. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens , 2016, European Neuropsychopharmacology.
[13] Matthew W. Johnson,et al. Classic hallucinogens in the treatment of addictions , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[14] Iain M McIntyre,et al. A Fatality Related to Two Novel Hallucinogenic Compounds: 4-Methoxyphencyclidine and 4-Hydroxy-N-methyl-N-ethyltryptamine. , 2015, Journal of analytical toxicology.
[15] V. Andreu,et al. Simultaneous determination of traditional and emerging illicit drugs in sediments, sludges and particulate matter. , 2015, Journal of chromatography. A.
[16] A. Janowsky,et al. Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function , 2013, Psychopharmacology.
[17] D. Horton,et al. A translational pharmacology approach to understanding the predictive value of abuse potential assessments , 2013, Behavioural pharmacology.
[18] Olof Beck,et al. Multicomponent LC-MS/MS screening method for detection of new psychoactive drugs, legal highs, in urine-experience from the Swedish population. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[19] A. Kjellgren,et al. Heaven and Hell—A Phenomenological Study of Recreational Use of 4-HO-MET in Sweden , 2011, Journal of psychoactive drugs.
[20] A. Janowsky,et al. Abuse Liability Profile of Three Substituted Tryptamines , 2011, Journal of Pharmacology and Experimental Therapeutics.
[21] R. Griffiths,et al. Principles of laboratory assessment of drug abuse liability and implications for clinical development. , 2009, Drug and alcohol dependence.
[22] M. Forster,et al. Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats , 2009, Psychopharmacology.
[23] G. Guzmán. Hallucinogenic Mushrooms in Mexico: An Overview , 2008, Economic Botany.
[24] R. de la Torre,et al. Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers. , 2008, Journal of pharmaceutical and biomedical analysis.
[25] K. Murnane,et al. The behavioral pharmacology of hallucinogens. , 2008, Biochemical pharmacology.
[26] Fabrizio Schifano,et al. Drugs on the web; the Psychonaut 2002 EU project , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[27] V. Watts,et al. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. , 2000, Journal of medicinal chemistry.
[28] J. C. Winter,et al. A comparison of N,N-dimethyltryptamine, harmaline, and selected congeners in rats trained with LSD as a discriminative stimulus , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[29] Alexander T. Shulgin,et al. Tihkal : The Continuation , 1997 .
[30] S. Peroutka,et al. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes , 1990, Neuropharmacology.
[31] K. Mellanby. Heaven and Hell , 1978, Nature.
[32] R. Mowbray,et al. HALLUCINOGENS , 1970, The Medical journal of Australia.
[33] S. L. Sherwood. Lysergic acid. , 1958, Medical world.